Pharmaceutical manufacturers of Trimetazidine

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of Caring for Life and deep-rooted community links wherever it is present, make it a partner of choice for global health bodies and stakeholders.

USV is a 60-year-old organization headquartered in Mumbai, generating approximately US$ 500 million in revenue, primarily from the Diabetic and Cardiac sectors. It is one of the top 15 companies in India, operating in over 60 countries and serving more than 100 satisfied customers with exports totaling around US$ 100 million. With 100+ product approvals globally and 30+ DMF submissions worldwide, USV provides value-added products in Oral Solids, Injectables (PFS, Vials), Ophthalmics, Biosimilars (Pegfilgrastim), and Peptides.

Bachem offers a comprehensive array of services to the pharmaceutical and biotechnology sectors. It specializes in creating innovative and efficient manufacturing procedures, as well as the dependable production of peptide-based active pharmaceutical ingredients. The company is headquartered in Switzerland and has branch offices in Europe, the United States, and Asia, thus ensuring a worldwide presence with greater expertise.

We have more than 20 years of experience providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs). Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

Servier, a multinational pharmaceutical company, leverages 60 years of experience in its integrated contract manufacturing division. The Servier Contract Manufacturing Partner provides a complete array of manufacturing, development, and packaging services for global delivery of drug substance and drug product. Servier's extensive institutional knowledge is enriched by state-of-the-art technologies.

A trusted Indian pharmaceutical company with strong people and technology capabilities, providing affordable, high-quality products that meet the healthcare needs of people across the globe.

Axyntis Group, established in 2007, is the foremost independent multi-location entity in the field of fine chemicals in France, generating an annual revenue of €90 million. Axyntis has evolved into a significant manufacturer of APIs in France through acquisitions and collaborations. It encompasses two sectors (colorants and fine chemicals) and emphasizes diversification and pioneering initiatives. The company operates three cGMP facilities in France, two of which are approved by the FDA. It offers CDMO services to partners for their API or advanced intermediate projects, from the initial development phase to the commercial stage, inclusive of preparative chromatography (Kyrapharm subsidiary). Additionally, it markets exclusive APIs.

Sichuan Xieli Pharmaceutical Co., Ltd. was founded in 1980 with the development concept of "Xieli Tongchuang Health Cause". It mainly engages in the cultivation of ecological medicinal materials, the extraction of natural active ingredients from animals and plants, and the synthesis and research of their derivatives. It is based on the production of high value-added export products. There are mainly dozens of varieties, including rutin based cardiovascular and cerebrovascular drugs, plant flavonoids based capillary drugs, plant derived anti-tumor drugs, animal and plant extracts, and pharmaceutical intermediates.

Reyoung Pharmaceutical Co., Ltd., established in 1966, is a modern comprehensive pharmaceutical company. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission “Reyoung Pharma., Benefit the public”, insists the business concept “Innovation is the basis, Product quality is first”. Never stop exploration and innovation, forging ahead with determination, and realizing the sustainable healthy development.

Nivedita Chemicals Pvt. Ltd. is presently an exporter of Active Pharmaceuticals Ingredients (API's) and Intermediates. We have been serving the pharmaceutical industry in India since 1972 and international market since 1987 with quality products. We are committed to help preserve life, and provide innovative yet affordable health care drugs. Anek Prayog Pvt. Ltd. is our sister concern, established by Late. Dr. Vasant Palkar in 1979. Anek Prayog Pvt Ltd. is the only manufacturing site of Nivedita Chemicals Pvt. Ltd. Nivedita Chemicals Pvt. Ltd. also takes care of the financial, marketing and R&D aspects of the business. Our goal is to manufacture vital drugs as import substitutes.